Salute e Benessere

Zymeworks Announces China NMPA Acceptance of Biologics License Application for…

Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product salesA Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer...
Nasdaq GlobeNewswire
10/06/2024

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with…

Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior successful Phase 2 symptoms trialRapid treatment effect on corneal inflammation was observed in TNFR1 genetic biomarker patients as early as Day 15 and was statistically significant at final efficacy visit on Day 43Licaminlimab was well tolerated similar to vehicle Company plans to...
Nasdaq GlobeNewswire
10/06/2024

India Breakthrough: Bio Regenerative Precision Medicine Seminar Held in…

This comeback is primarily focused on education, research, and biopharmaceutical production, cooperating with the research institutions in India such as the Council of Scientific & Industrial Research- Centre for Cellular & Molecular Biology (CSIR-CCM)'s Atal Incubation Centre (AIC), the Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru, International Institute of Information Technology (IIIT) Hyderabad, and others. This comeback is primarily focused on education…
PR Newswire
10/06/2024

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™)…

Poster Title: BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseasesPresenter: Dr Nick S. Laursen, Chief Scientific Officer and Co-Founder of Commit Biologics Poster Title:BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseasesPresenter:DrNick S. Laursen, Chief Scientific Officer and Co-Founder of Commit Biologics The data will reveal optimization of the...
PR Newswire
10/06/2024

Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society…

These data highlight the significantly higher tumor uptake and longer tumor retention leading to a higher tumor to background and tumor to kidney ratios of satoreotide which translates into higher pre-clinical efficacy than SST2-targeting agonists when labelled with isotopes, 225Ac-satoreotide and 177Lu-satoreotide. This demonstrates the potential for satoreotide to clinically outperform SST2-targeting agonists and strongly supports its further clinical development for the treatment of SST2…
PR Newswire
10/06/2024

XRP Healthcare Welcomes 10 Billion Dollar M&A Specialist Whitney Lynn to Head…

This strategic move comes as XRP Healthcare is set to embark on an ambitious mergers and acquisitions (M&A) venture, having successfully registered itstrademark inUganda . This crucial milestone paves the way for the consolidation, improvement, and integration of pharmacies, medical centres, and hospitals into a unified, high-performing conglomerate. Whitney Lynn'sappointment is also a crucial step in XRP Healthcare's journey towards operating as one cohesive entity,...
PR Newswire
10/06/2024

Nagase Viita Launches SOLBIOTE (TM), New Brand of Injectable-grade Saccharide…

Image1: SOLBIOTE (TM) portfolio; TREHALOSE SG and MALTOSE PH https://cdn.kyodonewsprwire.jp/prwfile/release/M104815/202406031668/_prw_PI1fl_MyQw9rBz.jpg Image1: SOLBIOTE (TM) portfolio; TREHALOSE SG and MALTOSE PHhttps://cdn.kyodonewsprwire.jp/prwfile/release/M104815/202406031668/_prw_PI1fl_MyQw9rBz.jpg Nagase Viita has a long history of harnessing the power of nature and an expertise in biotechnology, which led it to be the first to successfully mass produce trehalose utilizing starch...
PR Newswire
10/06/2024

J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain…

To-date, Partial Response (PR) has been confirmed in two patients and Stable Diseases in three other, including the patient with reduction of brain metastasis in Cohort 4 and two patients from the lower Cohorts at a lower dose. To-date, Partial Response (PR) has been confirmed in two patients and Stable Diseases in three other, including the patient with reduction of brain metastasis in Cohort 4 and two patients from the lower Cohorts at a lower dose. The final patient in Cohort 4 (100mg) is...
PR Newswire
10/06/2024

Rockit™ Apple fired up to Ready. Set. Rockit. into record season

Market Manager for the Middle East, Ziad El Chawa says 2024 is going to be a record year for Rockit in the Middle East, off the back of strong 31 percent growth in 2023 (versus 2022). Market Manager for theMiddle East,Ziad El Chawasays 2024 is going to be a record year for Rockit in theMiddle East, off the back of strong 31 percent growth in 2023 (versus 2022). "To drive consumer demand for increased volumes of Rockit™ apples arriving in market, we are focusing on interactive...
PR Newswire
10/06/2024

Distributor Orders Nexstim NBS System 5 for European Hospital

Press release, Helsinki, 10 June 2024 at 9 AM (EEST) Distributor Orders Nexstim NBS System 5 for European Hospital Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a distributor for a European hospital.The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech...
Nasdaq GlobeNewswire
10/06/2024

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV…

The test uses highly sensitive PCR technology, requiring only a single nasal-swab sample to provide rapid, accurate qualitative detection and differentiation among four of the most prevalent respiratory viruses for which differential diagnosis can drive appropriate treatment.Enables healthcare professionals to make confident clinical decisions and promptly determine appropriate treatment, with definitive results reported in just 20 minutes.Expands Roche's extensive molecular point of...
Nasdaq GlobeNewswire
10/06/2024

European Commission approves Roche's Alecensa as the first and only targeted…

European Commission approves Roche's Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive resected non-small cell lung cancer, as demonstrated in the Phase III ALINA study 1 Alecensa's approval addresses an urgent unmet need in the early-stage setting where about half of all people experience disease recurrence...
Nasdaq GlobeNewswire
10/06/2024

Santhera Announces Launch of Early Access Program in China for AGAMREE® by its…

Pratteln, Switzerland, June 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for AGAMREE® (vamorolone) in China for patients with Duchenne muscular dystrophy (DMD). In April 2024, the Hainan Medical Products Administration (HMPA) authorized the EAP for AGAMREE based on local policies, AGAMREE's existing overseas approvals (U.S., EU, UK) and its demonstrated ability to address urgent...
Nasdaq GlobeNewswire
10/06/2024

FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing…

Alzheimer's disease is a progressive disease caused by toxic amyloid proteins. Once established, this pathophysiological process continues through the patient's life and therefore sustained treatment is necessary. The treatment should be initiated as early as possible to maximize patient outcomes. Data from Studies 201, 301 and their OLEs show that continued treatment with LEQEMBI beyond the 18-month core phase prolongs the benefit as highly toxic protofibrils are continuously removed. If…
PR Newswire
10/06/2024

FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics…

TOKYO and CAMBRIDGE, Mass., June09, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI ® ) intravenous (IV) maintenance dosing. A Prescription...
Nasdaq GlobeNewswire
10/06/2024

Calyx / Invicro Forges a Strategic Collaboration with BAMF Health to Accelerate…

A catalyzing project for this partnership is an actinium-225 initiative, for which TerraPower is supplying actinium-225, and BAMF is leveraging its GE HealthCare StarGuide™ SPECT/CT and dosimetry expertise to enhance the study and application of actinium-225 in RLT. A catalyzing project for this partnership is an actinium-225 initiative, for which TerraPower is supplying actinium-225, and BAMF is leveraging its GE HealthCareStarGuide ™ SPECT/CT and dosimetry expertise to enhance the study and...
PR Newswire
07/06/2024

RECOMMENDED CASH OFFER for MARIADB PLC by MERIDIAN BIDCO LLC ("Bidco") which is…

MANHATTAN BEACH, Calif., June 7, 2024 /PRNewswire/ -- On 24 May 2024, Bidco and K1 announced that the offer document (the "Offer Document") in relation to Bidco's offer to acquire the entire issued and to be issued share capital of MariaDB plc (the "Offer") had been published and posted to shareholders of MariaDB plc. MANHATTAN BEACH, Calif.,June 7, 2024/PRNewswire/ -- On24 May 2024, Bidco and K1 announced that the offer document (the " Offer Document ") in relation…
PR Newswire
07/06/2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities…

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – June 7, 2024 – 07:00 PM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on June 7, 2024, from Atlas Special Opportunities, LLC indicating that as of June 7, 2024, it held...
Nasdaq GlobeNewswire
07/06/2024

PHAXIAM announces the availability of the preparatory documents for the Combined…

Lyon (France) and Cambridge (MA, US), 7 June 2024 - 5.45pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections,today announced the availability of preparatory documents for the Combined General Meeting of 28 June 2024. Shareholders of PHAXIAM Therapeutics are invited to attend the Combined General Meeting to be held on 28 June 2024 at 9:30 a.m. at the Company's registered...
Nasdaq GlobeNewswire
07/06/2024

ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia…

ILJIN SNT Co., Ltd. ("ILJIN") is a long-standing investor of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), and, together with its affiliates, currently holds more than 5% of Aurinia's common stock. ILJIN SNT Co., Ltd. (" ILJIN ") is a long-standing investor of Aurinia Pharmaceuticals Inc. (" Aurinia " or the " Company "), and, together with its affiliates, currently holds more than 5% of Aurinia's common stock. As one of…
PR Newswire
07/06/2024

deCODE genetics: The rate, nature and transmission of mitochondrial DNA…

Strong aggregate evidence was uncovered for selection against many such short-lived deleterious mtDNA mutations in the pedigrees. The deCODE team also reported evidence for an extensive earlier episode of negative selection affecting mitochondria, called germline selection, where poorly functioning mitochondrial DNA molecules are discarded during the development of oocytes. Finally, they used the large number of transmissisons of mtDNA mutations in the pedigrees to reliably estimate that…
PR Newswire
07/06/2024

Five-year data for Roche's Evrysdi show the majority of treated children with a…

After five years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past two years of age96% of Evrysdi-treated children could swallow, 80% could feed without a feeding tube and 59% could sit without support for at least 30 seconds Evrysdi is now approved in more than 100 countries with over 15,000 patients treated globallyBasel, 07 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new five-year data...
Nasdaq GlobeNewswire
07/06/2024

By 2029, the Autologous Stem Cell & Non-stem Cell Therapies Market is forecasted…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=837 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=837 Browse in-depth TOC on "Autologous Stem Cell & Non-stem Cell Therapies Market" 326 - Tables 49 - Figures 309 - Pages In 2023, autologous non-stem cell therapies held the largest share of the type segment in the autologous stem cell & non-stem cell therapies market. Autologous non-stem cell...
PR Newswire
07/06/2024

Abu Dhabi is Underway to Become a Global Pharmaceutical and Life Science…

In line with the Abu Dhabi Economic Vision 2030, the MoU is a pivotal step in Abu Dhabi's ongoing efforts to become a leading healthcare destination in the global healthcare landscape. The strategic partnership aims to create attractive value propositions for pharmaceutical, biotechnology, and medical technology companies to establish their operations in Abu Dhabi. By capitalising on DoH's world-class regulatory framework, ADIO's attractive investment platform, Etihad Cargo's expertise in air…
PR Newswire
07/06/2024
Altri  Comunicati